The phase 1 data from Allogene's ALPHA and ALPHA2 trials in relapsed/refractory large B-cell lymphoma is published, representing a milestone demonstrating the utility of allogeneic CAR-T therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback